Vir Biotechnology CEO Marianne De Backer to address Morgan Stanley Global Healthcare Conference

Vir Biotechnology CEO Marianne De Backer to address Morgan Stanley Global Healthcare Conference
Vir Biotechnology CEO set for conference

Vir Biotechnology announced that its President and CEO, Marianne De Backer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 7:45 a.m. ET.

The session will be webcast live, allowing viewers to hear De Backer discuss the company's recent developments and strategy in hepatitis delta and oncology. The event is expected to provide stakeholders with an update on Vir Biotechnology's corporate outlook and pipeline priorities.

Vir Biotechnology recently marked 10 years in business, outlining key scientific advances and organizational milestones in a company timeline. The firm also reported over $1.0 billion in cash as it advanced its CHD and oncology portfolios in its Q2 2026 financial results. These developments set the stage for the company’s updated strategy shared at the upcoming conference.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.